Is Cabaletta Bio Stock a Good Investment?
Cabaletta Bio Investment Advice | CABA |
- Examine Cabaletta Bio's financial health by looking at its balance sheet, income statement, and cash flow statement. Analyze key financial ratios, such as Price-to-Earnings (P/E), Price-to-Sales (P/S), and Price-to-Book (P/B), to determine whether the stock is fairly valued or over/undervalued.
- Research Cabaletta Bio's leadership team and their track record. Good management can help Cabaletta Bio navigate difficult times and make strategic decisions that benefit shareholders and increases its net worth.
- Consider the overall health of the Biotechnology space and any emerging trends that could impact Cabaletta Bio's business and its evolving consumer preferences.
- Compare Cabaletta Bio's performance and market position to its competitors. Analyze how Cabaletta Bio is positioned in terms of product offerings, innovation, and market share.
- Check if Cabaletta Bio pays a dividend and its dividend yield and payout ratio.
- Review what financial analysts are saying about Cabaletta Bio's stock and their price targets. However, remember that analysts' opinions can vary, and their predictions may not always be accurate.
It's important to note that investing in Cabaletta Bio stock, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember that it's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. Below is a detailed guide on how to decide if Cabaletta Bio is a good investment.
Sell | Buy |
Cautious Hold
Market Performance | Very Weak | Details | |
Volatility | Relatively risky | Details | |
Hype Condition | Over hyped | Details | |
Current Valuation | Undervalued | Details | |
Odds Of Distress | Low | Details | |
Economic Sensitivity | Hyperactively responds to market trends | Details | |
Investor Sentiment | Alarmed | Details | |
Analyst Consensus | Strong Buy | Details | |
Financial Strenth (F Score) | Poor | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unlikely Manipulator | Details |
Examine Cabaletta Bio Stock
Researching Cabaletta Bio's stock involves analyzing various aspects of the company and its industry to make an informed investment decision. The key areas to focus on are fundamentals, business model and competitive advantage. It is also important to analyze trends in revenue, net income, and cash flow, as well as key financial ratios, such as price-to-earnings (P/E), price-to-sales (P/S), and debt-to-equity (D/E). About 97.0% of the company shares are held by institutions such as insurance companies. The company has price-to-book (P/B) ratio of 0.52. Some equities with similar Price to Book (P/B) outperform the market in the long run. Cabaletta Bio recorded a loss per share of 2.16. The entity had not issued any dividends in recent years.
To determine if Cabaletta Bio is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Cabaletta Bio's research are outlined below:
| Cabaletta Bio generated a negative expected return over the last 90 days | |
| Cabaletta Bio has high historical volatility and very poor performance | |
| Net Loss for the year was (67.67 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Cabaletta Bio currently holds about 96.81 M in cash with (53.55 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 3.34, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Cabaletta Bio has a poor financial position based on the latest SEC disclosures | |
| Over 97.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from news.google.com: Cabaletta Bios SWOT analysis CAR-T pioneers stock faces pivotal moment - Investing.com |
Cabaletta Bio Quarterly Liabilities And Stockholders Equity |
|
Cabaletta Bio uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Cabaletta Bio. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Cabaletta Bio's previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 21st of March 2024 Upcoming Quarterly Report | View | |
| 9th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 21st of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Earnings surprises can significantly impact Cabaletta Bio's stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate. Below are the table of largest EPS Surprises Cabaletta Bio's investors have experienced.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2021-03-16 | 2020-12-31 | -0.36 | -0.4 | -0.04 | 11 | ||
2020-08-06 | 2020-06-30 | -0.39 | -0.35 | 0.04 | 10 | ||
2022-08-11 | 2022-06-30 | -0.5 | -0.45 | 0.05 | 10 | ||
2021-11-01 | 2021-09-30 | -0.5 | -0.45 | 0.05 | 10 | ||
2021-08-05 | 2021-06-30 | -0.5 | -0.45 | 0.05 | 10 | ||
2021-05-03 | 2021-03-31 | -0.46 | -0.41 | 0.05 | 10 | ||
2024-03-21 | 2023-12-31 | -0.39 | -0.46 | -0.07 | 17 | ||
2023-08-10 | 2023-06-30 | -0.44 | -0.37 | 0.07 | 15 |
Know Cabaletta Bio's Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Cabaletta Bio is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Cabaletta Bio backward and forwards among themselves. Cabaletta Bio's institutional investor refers to the entity that pools money to purchase Cabaletta Bio's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Sofinnova Ventures | 2024-06-30 | 1.2 M | Commodore Capital Lp | 2024-09-30 | 1.1 M | Geode Capital Management, Llc | 2024-09-30 | 1.1 M | Jpmorgan Chase & Co | 2024-06-30 | 956.7 K | Millennium Management Llc | 2024-06-30 | 698.3 K | Point72 Asset Management, L.p. | 2024-09-30 | 667.3 K | Victory Capital Management Inc. | 2024-09-30 | 629.1 K | Morgan Stanley - Brokerage Accounts | 2024-06-30 | 591 K | T. Rowe Price Associates, Inc. | 2024-06-30 | 582.3 K | Jennison Associates Llc | 2024-09-30 | 5.6 M | Blackrock Inc | 2024-06-30 | 4.8 M |
Cabaletta Bio's market capitalization trends
The company currently falls under 'Small-Cap' category with a current market capitalization of 111.93 M.Market Cap |
|
Cabaletta Bio's profitablity analysis
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.27) | (0.28) | |
| Return On Capital Employed | (0.31) | (0.30) | |
| Return On Assets | (0.27) | (0.28) | |
| Return On Equity | (0.29) | (0.27) |
Determining Cabaletta Bio's profitability involves analyzing its financial statements and using various financial metrics to determine if Cabaletta Bio is a good buy. For example, gross profit margin measures Cabaletta Bio's profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Cabaletta Bio's profitability and make more informed investment decisions.
Please note, the presentation of Cabaletta Bio's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Cabaletta Bio's management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Cabaletta Bio's management manipulating its earnings.
Evaluate Cabaletta Bio's management efficiency
Cabaletta Bio has return on total asset (ROA) of (0.3113) % which means that it has lost $0.3113 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.4816) %, meaning that it created substantial loss on money invested by shareholders. Cabaletta Bio's management efficiency ratios could be used to measure how well Cabaletta Bio manages its routine affairs as well as how well it operates its assets and liabilities. As of November 26, 2024, Return On Tangible Assets is expected to decline to -0.28. The current year's Return On Capital Employed is expected to grow to -0.3. At present, Cabaletta Bio's Total Assets are projected to increase significantly based on the last few years of reporting. The current year's Non Current Assets Total is expected to grow to about 9.6 M, whereas Net Tangible Assets are forecasted to decline to about 84 M.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 5.77 | 6.06 | |
| Tangible Book Value Per Share | 5.77 | 6.06 | |
| Enterprise Value Over EBITDA | (10.12) | (9.62) | |
| Price Book Value Ratio | 3.94 | 4.13 | |
| Enterprise Value Multiple | (10.12) | (9.62) | |
| Price Fair Value | 3.94 | 4.13 | |
| Enterprise Value | 224.2 M | 153.2 M |
Cabaletta Bio's management has consistently demonstrated strong leadership, driving both financial growth and operational excellence. By analyzing current market trends and future growth opportunities, we assess the stock's true value and potential for investors.
Beta 2.419 |
Basic technical analysis of Cabaletta Stock
As of the 26th of November, Cabaletta Bio shows the mean deviation of 5.19, and Risk Adjusted Performance of (0.13). Cabaletta Bio technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices.Cabaletta Bio's insider trading activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Cabaletta Bio insiders, such as employees or executives, is commonly permitted as long as it does not rely on Cabaletta Bio's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Cabaletta Bio insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Cabaletta Bio's Outstanding Corporate Bonds
Cabaletta Bio issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Cabaletta Bio uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Cabaletta bonds can be classified according to their maturity, which is the date when Cabaletta Bio has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Boeing Co 2196 Corp BondUS097023DG73 | View | |
| CA INC 47 Corp BondUS12673PAJ49 | View | |
| HSBC Holdings PLC Corp BondUS404280DR76 | View | |
| CW Senior Financing Corp BondUS12674TAA43 | View | |
| MGM Resorts International Corp BondUS552953CD18 | View | |
| HEXWIN 5375 31 OCT 26 Corp BondUS12674CAA18 | View | |
| AerCap Global Aviation Corp BondUS00773HAA59 | View |
Understand Cabaletta Bio's technical and predictive indicators
Using predictive indicators to make investment decisions involves analyzing Cabaletta Bio's various financial and market-based factors to help forecast future trends and identify investment opportunities. Select the indicators that are most relevant to your investment strategy. Each indicator has its own strengths and weaknesses, so it's essential to combine multiple indicators to get a more comprehensive view of the market and reduce the risk of making poor decisions based on limited data.
| Risk Adjusted Performance | (0.13) | |||
| Market Risk Adjusted Performance | (0.31) | |||
| Mean Deviation | 5.19 | |||
| Coefficient Of Variation | (557.36) | |||
| Standard Deviation | 6.86 | |||
| Variance | 47.01 | |||
| Information Ratio | (0.20) | |||
| Jensen Alpha | (1.70) | |||
| Total Risk Alpha | (2.30) | |||
| Treynor Ratio | (0.32) | |||
| Maximum Drawdown | 30.64 | |||
| Value At Risk | (10.89) | |||
| Potential Upside | 8.23 | |||
| Skewness | 0.2828 | |||
| Kurtosis | 1.69 |
| Risk Adjusted Performance | (0.13) | |||
| Market Risk Adjusted Performance | (0.31) | |||
| Mean Deviation | 5.19 | |||
| Coefficient Of Variation | (557.36) | |||
| Standard Deviation | 6.86 | |||
| Variance | 47.01 | |||
| Information Ratio | (0.20) | |||
| Jensen Alpha | (1.70) | |||
| Total Risk Alpha | (2.30) | |||
| Treynor Ratio | (0.32) | |||
| Maximum Drawdown | 30.64 | |||
| Value At Risk | (10.89) | |||
| Potential Upside | 8.23 | |||
| Skewness | 0.2828 | |||
| Kurtosis | 1.69 |
Consider Cabaletta Bio's intraday indicators
Cabaletta Bio intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Cabaletta Bio stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
| Accumulation Distribution | 904090.0 | |||
| Daily Balance Of Power | 0.2407 | |||
| Rate Of Daily Change | 1.06 | |||
| Day Median Price | 2.65 | |||
| Day Typical Price | 2.57 | |||
| Price Action Indicator | (0.17) | |||
| Period Momentum Indicator | 0.13 |
Cabaletta Bio Corporate Filings
8K | 18th of November 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
13A | 12th of November 2024 An amended filing to the original Schedule 13G | ViewVerify |
13A | 22nd of August 2024 The form used by investors holding more than 5% of a company's stock, to report their beneficial ownership pursuant to Rule 13d-1 or Rule 13d-2 under the Securities Exchange Act of 1934 | ViewVerify |
| 23rd of April 2024 Other Reports | ViewVerify |
Cabaletta Stock media impact
Far too much social signal, news, headlines, and media speculation about Cabaletta Bio that are available to investors today. That information is available publicly through Cabaletta media outlets and privately through word of mouth or via Cabaletta internal channels. However, regardless of the origin, that massive amount of Cabaletta data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Cabaletta Bio news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Cabaletta Bio relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Cabaletta Bio's headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Cabaletta Bio alpha.
Cabaletta Bio Sentiment by Major News Outlets
Investor sentiment, mood or attitude towards Cabaletta Bio can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Cabaletta Bio Corporate Management
| Samik MD | Chief Officer | Profile | |
| Steven MD | Chairman, CoFounder | Profile | |
| FACR MD | Chief Officer | Profile | |
| Michael JD | General Secretary | Profile | |
| Heather MSc | Chief Officer | Profile | |
| Qing Yuan | Chief Officer | Profile | |
| Aimee MD | CoFounder Board | Profile |
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Cabaletta Bio. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of labor statistics. For information on how to trade Cabaletta Stock refer to our How to Trade Cabaletta Stock guide.You can also try the Equity Valuation module to check real value of public entities based on technical and fundamental data.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Cabaletta Bio. If investors know Cabaletta will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Cabaletta Bio listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.16) | Return On Assets (0.31) | Return On Equity (0.48) |
The market value of Cabaletta Bio is measured differently than its book value, which is the value of Cabaletta that is recorded on the company's balance sheet. Investors also form their own opinion of Cabaletta Bio's value that differs from its market value or its book value, called intrinsic value, which is Cabaletta Bio's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Cabaletta Bio's market value can be influenced by many factors that don't directly affect Cabaletta Bio's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
In summary, please note that there is a difference between Cabaletta Bio's value and its price, as these two are different measures arrived at by various means. Investors typically determine if Cabaletta Bio is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Cabaletta Bio's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.